** Brokerage H.C. Wainwright starts coverage of drug developer Artiva Biotherapeutics ARTV.O with "buy" rating and PT of $20
** PT represents an ~88% upside to stock's last close
** Co is testing its experimental drug, AlloNK, for an autoimmune disease called systemic lupus erythematosus $(SLE)$ in combination with antibodies Rituxan or Gazyva
** SLE is a condition where the immune system attacks the body's own tissues
** Brokerage notes "current treatment options do not effectively control disease progression"
** Says AlloNK costs less than $6,000 per patient for ARTV to produce, compared to ~$100,000 for auto-CAR T therapies
** Co has capacity to produce enough AlloNK for over 1,000 autoimmune patients annually, H.C. Wainwright says
** Brokerage expects AlloNK to launch by 2029 and forecasts sales to grow to $531 mln by 2031
** As of last close, stock has fallen ~34% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。